Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines various immunomodulatory therapies for cutaneous lymphoma and notes that they are most effective in the disease's early stages.

In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.

In this study, topical CUR61414 was effective in inhibiting basal cell carcinomas in mice, but no clinical activity was observed in human trials.

In preclinical studies, topical CUR61414 reduced Hh signaling and shrank BCCs in mice, but this study found no clinical efficacy in human superficial or nodular BCCs.

This study identified a genetic locus associated with rhabdomyosarcoma susceptibility in mice and found that specific differentiation markers are linked to the regression of basal cell carcinoma.